Business Wire

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at ...

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced that final results from the Phase 3 METIS trial of Tumor Treating Fields (TTFields) therapy for brain metastases from non-small ...
News Medical

Radiotherapy may be unnecessary for many breast cancer patients after mastectomy

Radiotherapy can be safely omitted as a treatment for many breast cancer patients who have had a mastectomy and are taking anti-cancer drugs, a study shows. An international trial found that patients ...
Medscape

R/R B-Cell ALL: Obe-Cel Shows Sustained Benefit

More than a third of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with the CAR T-cell therapy obecabtagene autoleucel (obe-cel) remained in remission at a ...
Frontiers

Advanced Nanocarriers for Cancer Therapy: Design Strategies, Theragnostic Approaches, Preclinical Development and Clinical Translation

Cancer remains a leading cause of global morbidity and mortality, and conventional therapeutic strategies are often limited by poor tumor selectivity, ...
ascopubs.org

A phase I/II trial of high-dose methotrexate (HDMTX) followed by prophylactic glucarpidase in patients with impaired renal function and central nervous system lymphoma (CNSL).

Second primary malignancy in patients with diffuse large B-cell lymphoma (DLBCL) receiving chimeric antigen receptor T-cell (CAR T) therapy and other systemic anti-cancer therapy: A real-world data ...
News Medical

Progesterone mimic plus anti-estrogen treatment slows tumor growth in breast cancer patients

A drug mimicking the hormone progesterone has anti-cancer activity when used together with conventional anti-estrogen treatment for women with breast cancer, a new Cambridge-led trial has found. A low ...